24500EGP
- Active ingredient
- blood-coagulation factor viii inhibitor bypassing activity
- Strength
- 1000 i.u. / 20 ml
- Form
- vial
- Manufacturer
- takeda
- Route
- injection
Uses
Used for prevention and treatment of bleeding episodes in patients with hemophilia who have developed factor VIII or IX inhibitors.
Do not use if
Known hypersensitivity to product components.
Side effects
Fever, infusion-related reactions, headache, and thrombotic events may occur.
Warnings
Monitor for signs of thrombosis and disseminated intravascular coagulation.
How it works
Provides bypassing coagulation activity that promotes clot formation despite the presence of factor inhibitors.
Storage
Store according to manufacturer instructions, usually refrigerated.
